Cargando…

Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity

BACKGROUND: Previous studies have suggested that people with obesity showed elevated serum levels of leptin as well as lipid dysfunction and proprotein convertase subtilisin/kexin type 9 (PCSK9) played an important role in the regulation of lipid metabolism recently. The aim of this study was to det...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Ying, Li, Sha, Cui, Chuan-Jue, Zhang, Yan, Yang, Sheng-Hua, Li, Jian-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035475/ https://www.ncbi.nlm.nih.gov/pubmed/27663646 http://dx.doi.org/10.1186/s12967-016-1032-4

Ejemplares similares

Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
por: Azar, Yara, et al.
Publicado: (2022)

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
por: Kosenko, Tanja, et al.
Publicado: (2013)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
por: Mohamed, Farzahna, et al.
Publicado: (2023)

PCSK9 inhibition: the way forward in the treatment of dyslipidemia
por: Stoekenbroek, Robert M., et al.
Publicado: (2015)

PCSK9 Gene Participates in the Development of Primary Dyslipidemias
por: Matías-Pérez, D, et al.
Publicado: (2021)

Ineffective Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Monotherapy in Dyslipidemia with Low-Density Lipoprotein Cholesterol (LDL-C) Receptor Abnormalities: A Report of 2 Cases
por: Matta, Anthony, et al.
Publicado: (2020)

PCSK9 and triglyceride-rich lipoprotein metabolism
por: Druce, Irena, et al.
Publicado: (2015)

Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor
por: Duff, Christopher J., et al.
Publicado: (2009)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor
por: Johns, Douglas G., et al.
Publicado: (2023)

Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation
por: Rymer, Jennifer A., et al.
Publicado: (2020)

PCSK9 Inhibition: Does Lipoprotein Size Matter?
por: Si‐Tayeb, Karim, et al.
Publicado: (2015)

Lipoprotein(a) and PCSK9 inhibition: clinical evidence
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease
por: Xu, Rui-Xia, et al.
Publicado: (2014)

A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles
por: Sarkar, Samantha K., et al.
Publicado: (2020)

Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9
por: Nava-Salazar, Sonia, et al.
Publicado: (2022)

PCSK9: The Nexus of Lipoprotein Metabolism and Inflammation in COVID-19
por: Goonewardena, Sascha N., et al.
Publicado: (2023)

Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
por: Li, Tingting, et al.
Publicado: (2021)

Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein?
por: Cesaro, Arturo, et al.
Publicado: (2022)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
por: Kohli, Payal, et al.
Publicado: (2016)

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
por: Reyes-Soffer, Gissette, et al.
Publicado: (2017)

Role of leptin on the expression of low density lipoprotein receptor
por: Yadav, Naval Kishor, et al.
Publicado: (2014)

Decreased PCSK9 expression in human hepatocellular carcinoma
por: Bhat, Mamatha, et al.
Publicado: (2015)

Dyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing
por: Jia, Yan-Jun, et al.
Publicado: (2013)

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol
por: Poirier, Steve, et al.
Publicado: (2013)

Study on Regulation of Low Density Lipoprotein Cholesterol Metabolism using PCSK9 Gene Silencing: A computational Approach
por: Vijayaraghavan, Bhooma, et al.
Publicado: (2018)

Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels
por: Lee, Chan Joo, et al.
Publicado: (2017)

Interaction between adipocytes and high-density lipoprotein:new insights into the mechanism of obesity-induced dyslipidemia and atherosclerosis
por: Zhang, Tianhua, et al.
Publicado: (2019)

Common and Rare PCSK9 Variants Associated with Low-Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian Randomization Study
por: Hsu, Lung-An, et al.
Publicado: (2022)

Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
por: Lipari, Michael T., et al.
Publicado: (2012)

High Density Lipoprotein Particle Size in Children: Relation to Atherogenic Dyslipidemia
por: Numata, Michio
Publicado: (2004)

Lupin Peptides Modulate the Protein-Protein Interaction of PCSK9 with the Low Density Lipoprotein Receptor in HepG2 Cells
por: Lammi, Carmen, et al.
Publicado: (2016)

Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Low‐Density Lipoprotein Cholesterol
por: Leucker, Thorsten M., et al.
Publicado: (2018)

High-Throughput Screening Identifies MicroRNAs Regulating Human PCSK9 and Hepatic Low-Density Lipoprotein Receptor Expression
por: van Solingen, Coen, et al.
Publicado: (2021)

Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice
por: Kawakami, Ryo, et al.
Publicado: (2018)

Decreased Efficiency of Very-Low-Density Lipoprotein Lipolysis Is Linked to Both Hypertriglyceridemia and Hypercholesterolemia, but It Can Be Counteracted by High-Density Lipoprotein
por: Wieczorek, Ewa, et al.
Publicado: (2021)

Ticagrelor suppresses oxidized low-density lipoprotein-induced endothelial cell apoptosis and alleviates atherosclerosis in ApoE(−/−) mice via downregulation of PCSK9
por: Xia, Xiaodong, et al.
Publicado: (2019)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

PCSK9 mediates the oxidative low-density lipoprotein-induced pyroptosis of vascular endothelial cells via the UQCRC1/ROS pathway
por: Zeng, Junfa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fouf4f31s95prnqcr7jtbvsotu